Electroporation Instruments MarketSize and Trends

Global electroporation instrument market is estimated to be valued at US$ 232.19 Mn in 2022 and is expected to reach US$ 328.53 Mn by 2030, exhibiting a CAGR of 4.4% during the forecast period (2022-2030).

Figure 1. Global Electroporation Instruments Market (%) in Terms of Value, By Region, 2022

Increasing prevalence of cancer is the major factor that is expected to drive growth of the global electroporation instruments market over the forecast period.

Increasing prevalence of cancer, is the major factor that is expected to drive growth of the global electroporation instruments market over the forecast period. For instance, according to the World Health Organization report 2020, cancer was the leading cause of death in the world, accounting for around ten million deaths in 2020 worldwide. In terms of new cancer cases worldwide, the most common were: 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.4 million cases of prostate cancer, 1.20 million cases of skin cancer, 1.93 million cases of coon & rectum cancer, and 1.09 million cases of stomach cancer. According to the American Cancer Society 2020 report, around 1.8 million new cancer cases were diagnosed and 606,520 deaths by cancer in the U.S. in 2020 were reported.

Figure 2: Global Electroporation Instruments Market Share (%), by Product Type, 2022

Increasing product approvals and launches are expected to drive growth of the global electroporation instruments market during the forecast period

Increasing product approvals and launches are expected to drive growth of the global electroporation instruments market during the forecast period. For instance, on April 2, 2022, Thermo Fisher Scientific Inc., an American supplier of scientific instrumentation, reagents and consumables, and software services announced the launch of Gibco CTS Xenon Electroporation System. The product is intended to enable the development of cell therapies. Moreover, on June 25, 2020, MaxCyte, a global clinical-stage cell-based medicines and life sciences company, announced the launched of the first product in its new and expanded ExPERT disposables line. The R-1000 cuvette can process a volume of up to one mL, or up to 200 million cells, and offers greater versatility for companies developing cell therapy drugs, as well as those advancing early drug discovery. These new cuvette designs can be used across the entire range of MaxCyte's electroporation instrumentation.